66,100 Shares in LifeStance Health Group, Inc. $LFST Bought by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp bought a new stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 66,100 shares of the company’s stock, valued at approximately $708,000.

Other hedge funds also recently made changes to their positions in the company. Silversmith Partners I GP LLC purchased a new stake in LifeStance Health Group during the fourth quarter worth about $100,842,000. First Eagle Investment Management LLC boosted its stake in LifeStance Health Group by 13.3% in the fourth quarter. First Eagle Investment Management LLC now owns 1,496,466 shares of the company’s stock valued at $10,535,000 after acquiring an additional 176,000 shares during the last quarter. Moran Wealth Management LLC bought a new position in shares of LifeStance Health Group during the 1st quarter valued at approximately $953,000. Orbimed Advisors LLC bought a new position in shares of LifeStance Health Group during the 1st quarter valued at approximately $3,185,000. Finally, Renaissance Technologies LLC increased its stake in shares of LifeStance Health Group by 92.5% during the 1st quarter. Renaissance Technologies LLC now owns 800,500 shares of the company’s stock worth $5,099,000 after purchasing an additional 384,600 shares during the last quarter. 85.50% of the stock is currently owned by institutional investors.

LifeStance Health Group Trading Up 1.2%

NASDAQ:LFST opened at $12.30 on Friday. LifeStance Health Group, Inc. has a 1 year low of $4.77 and a 1 year high of $12.97. The stock’s fifty day moving average price is $11.13 and its two-hundred day moving average price is $8.57. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.38 and a quick ratio of 1.38. The company has a market cap of $4.77 billion, a P/E ratio of 94.62 and a beta of 1.14.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $435.35 million for the quarter, compared to analyst estimates of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The firm’s revenue for the quarter was up 26.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.01) EPS. As a group, analysts expect that LifeStance Health Group, Inc. will post 0.16 EPS for the current year.

Insider Buying and Selling

In other news, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.62, for a total value of $144,890,858.34. Following the completion of the transaction, the insider directly owned 98,101,407 shares in the company, valued at approximately $1,041,836,942.34. This trade represents a 12.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert Bessler sold 894,337 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $10.13, for a total transaction of $9,059,633.81. Following the transaction, the director directly owned 539,763 shares of the company’s stock, valued at approximately $5,467,799.19. This represents a 62.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 14,629,850 shares of company stock worth $154,952,012 over the last quarter. 3.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Weiss Ratings raised LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. Canaccord Genuity Group boosted their target price on LifeStance Health Group from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Barclays upped their price target on LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a research report on Tuesday, July 14th. Zacks Research lowered LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Finally, BTIG Research upped their price objective on shares of LifeStance Health Group from $16.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, August 19th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $12.38.

LifeStance Health Group Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.